Cognitive profile of aging and dementia
Acknowledgments This work was supported by National Institutes of Health grants: P01 HD035897, U54 HD079123, U01 AG051412, and R01 AG014673 as well as funds from the New York State Office…
Fluid biomarkers for Alzheimer’s disease in Down syndrome: Current status and novel trends
Introduction As mentioned in Chapter 1, people with Down syndrome (DS) develop Alzheimer’s disease (AD) neuropathology by 40 years of age (Chapter 2), and in most, dementia develops in their…
Genetics of Alzheimer’s disease in adults with Down syndrome
Alzheimer’s disease in adults with Down syndrome As described in Chapter 1, Down syndrome (DS) is one of the most common genetic diseases. Adults with DS carry three copies of…
Psychiatric issues in aging and dementia
Epidemiology While the prevalence rates of physical health conditions, and in particular Alzheimer’s disease (AD), in people with Down syndrome (DS) have been extensively researched [1, 2] (also see Chapters…
Contributions of the neurological examination to the diagnosis of dementia in Down syndrome
Chapter 13: Contributions of the neurological examination to the diagnosis of dementia in Down syndrome Ira T. Lotta,*; H. Diana Rosasb,,c; Florence Laib; Shahid Zamand a Department of Pediatrics, School of…
Proteomic and metabolomic biomarkers of Alzheimer’s disease: Opportunities to advance precision medicine and clinical trials
Proteomic and metabolomic methodologies In the general AD population, proteomic and metabolomic studies are under close scrutiny as inconsistency in outcomes and variability in preanalytic methods (sample collection, processing, storage,…
Co-occurring medical conditions in aging adults with Down syndrome
Prevalence The prevalence of Down syndrome (DS) in the United States is believed to be about 8.27 per 10,000 persons. Based upon birth prevalence and death certificate data the US…
